Volume 31, Issue 4 (February 2024)
J Birjand Univ Med Sci. 2024, 31(4): 282-292 |
Back to browse issues page
Research code: 456053
Ethics code: IR.BUMS.REC.1400.169
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Seifi A, Naseri K, Ramazani A A, Ramezani M, Avan R. Prevalence of drug interactions and its related factors in patients with epilepsy referred to Razi Hospital in Birjand. J Birjand Univ Med Sci. 2024; 31 (4) :282-292
URL: http://journal.bums.ac.ir/article-1-3385-en.html
URL: http://journal.bums.ac.ir/article-1-3385-en.html
1- Medical Student, Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
2- Department of Pharmacology, School of Pharmacy, Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran
3- Department of Epidemiology and Biostatistics, Faculty of Health, Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran
4- Pharmacy Student, Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
5- Department of Clinical Pharmacy, School of Pharmacy, Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran ,avanr91@gmail.com
2- Department of Pharmacology, School of Pharmacy, Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran
3- Department of Epidemiology and Biostatistics, Faculty of Health, Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran
4- Pharmacy Student, Student Research Committee, Birjand University of Medical Sciences, Birjand, Iran
5- Department of Clinical Pharmacy, School of Pharmacy, Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand, Iran ,
Abstract: (391 Views)
Background and Aims: Epilepsy is the most common chronic neurological disorder, with approximately 80% of people suffering from epilepsy in developing countries. Due to the importance of drug interactions among antiepileptic drugs, this study aimed to determine the prevalence of drug interactions between antiepileptic drugs and other drugs, as well as associated factors.
Materials and Methods: In this descriptive-analytical study, 300 patients with epilepsy referring to Razi Hospital in Birjand in 2020 were studied. The patients receiving at least two drugs were included in the study. Drug interactions were evaluated in Lexicomp® software. The data was entered into SPSS19 software. The Chi-square, Fisher's tests, and logistic regression were used for data analysis.
Results: The results showed that 154 patients (51%) were women in this study. The mean age of the patients was 45.12±16.20 years. 220 (73.3%) had drug interactions, and 111 (50.5%) had polypharmacy. The number of 1,147 drugs were prescribed, and 939 drug interactions were reported, of which 680 (72.4%) were moderate type C, 94 (10%) were major type D, 97 (10.3%) were major type C, 45 (4.8%) were moderate type D, and 23 (2.4%) were mild type B. The variables of occupation, type of epilepsy, medical history, education level, and age were effective in drug interactions of the patient.
Conclusion: This study showed the importance of awareness of drug interactions in patients with epilepsy. The presence of a clinical pharmacist can be effective in preventing such interactions in hospitalized patients.
Materials and Methods: In this descriptive-analytical study, 300 patients with epilepsy referring to Razi Hospital in Birjand in 2020 were studied. The patients receiving at least two drugs were included in the study. Drug interactions were evaluated in Lexicomp® software. The data was entered into SPSS19 software. The Chi-square, Fisher's tests, and logistic regression were used for data analysis.
Results: The results showed that 154 patients (51%) were women in this study. The mean age of the patients was 45.12±16.20 years. 220 (73.3%) had drug interactions, and 111 (50.5%) had polypharmacy. The number of 1,147 drugs were prescribed, and 939 drug interactions were reported, of which 680 (72.4%) were moderate type C, 94 (10%) were major type D, 97 (10.3%) were major type C, 45 (4.8%) were moderate type D, and 23 (2.4%) were mild type B. The variables of occupation, type of epilepsy, medical history, education level, and age were effective in drug interactions of the patient.
Conclusion: This study showed the importance of awareness of drug interactions in patients with epilepsy. The presence of a clinical pharmacist can be effective in preventing such interactions in hospitalized patients.
Type of Study: Original Article |
Subject:
Pharmacy
Received: 2023/09/3 | Accepted: 2025/01/4 | ePublished ahead of print: 2025/02/15 | ePublished: 2024/12/25
Received: 2023/09/3 | Accepted: 2025/01/4 | ePublished ahead of print: 2025/02/15 | ePublished: 2024/12/25
References
1. Kvalsund MP, Birbeck GL. Epilepsy care challenges in developing countries. Curr Opin Neurol. 2012;25(2):179-86. DOI: 10.1097/WCO.0b013e328350baf8 [DOI:10.1097/WCO.0b013e328350baf8] [PMID]
2. Beghi E. The epidemiology of epilepsy. Neuroepidemiology. 2020;54(2):185-91. DOI: 10.1159/000503831 [DOI:10.1159/000503831] [PMID]
3. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279-86. DOI: 10.1001/jamaneurol.2017.3949 [DOI:10.1001/jamaneurol.2017.3949] [PMID] []
4. Dwivedi R, Tiwari P, Pahuja M, Dada R, Tripathi M. Anti-seizure medications and quality of life in person with epilepsy. Heliyon. 2022;8(10). DOI: 10.1016/j.heliyon.2022.e11073 [DOI:10.1016/j.heliyon.2022.e11073] [PMID] []
5. Fattorusso A, Matricardi S, Mencaroni E, Dell'Isola GB, Di Cara G, Striano P, et al. The pharmacoresistant epilepsy: an overview on existant and new emerging therapies. Front Neurol. 2021; 12: 674483. DOI: 10.3389/fneur.2021.674483 [DOI:10.3389/fneur.2021.674483] [PMID] []
6. Bosak M, Słowik A, Iwańska A, Lipińska M, Turaj W. Co-medication and potential drug interactions among patients with epilepsy. Seizure. 2019; 66: 47-52. DOI: 10.1016/j.seizure.2019.01.014 [DOI:10.1016/j.seizure.2019.01.014] [PMID]
7. Reimers A. Contraception for women with epilepsy: counseling, choices, and concerns. Open Access J Contracept. 2016; 7: 69-76. DOI: 10.2147/OAJC.S85541 [DOI:10.2147/OAJC.S85541] [PMID] []
8. Hebbar S. Epilepsy and oral hormonal contraception-Indian perspective. Int J Pharm Pharm Sci. 2017; 9(3): 1-6. DOI: 10.22159/ijpps.2017v9i3.16540 [DOI:10.22159/ijpps.2017v9i3.16540]
9. Parekh K, Kravets HD, Spiegel R. Special Considerations in the Management of Women with Epilepsy in Reproductive Years. J Pers Med. 2022; 12(1): 88. DOI: 10.3390/jpm12010088 [DOI:10.3390/jpm12010088] [PMID] []
10. SHARMA B, SAKSHI P. Interactions Between Anti-Epileptic Drugs and Contraceptives: A Review. Int Healthc Res J. 2021; 5(1): RV14-RV18. DOI: 10.26440/IHRJ/0501.04409 [DOI:10.26440/IHRJ/0501.04409]
11. Hughes JE, Bennett KE, Cahir C. Drug-Drug Interactions and Their Association with Adverse Health Outcomes in the Older Community-Dwelling Population: A Prospective Cohort Study. Clin. Drug Investig. 2024; 44(6): 439-53. DOI: 10.1007/s40261-024-01369-9 [DOI:10.1007/s40261-024-01369-9] [PMID] []
12. Batel Marques F, Penedones A, Mendes D, Alves C. A systematic review of observational studies evaluating costs of adverse drug reactions. Clinicoecon Outcomes Res. 2016; 8: 413-26. DOI: 10.2147/CEOR.S115689 [DOI:10.2147/CEOR.S115689] [PMID] []
13. Namazi S, Pourhatami S, Borhani-Haghighi A, Roosta S. Incidence of potential drug-drug interaction and related factors in hospitalized neurological patients in two Iranian teaching hospitals.Iran J Med Sci. 2014; 39(6): 515-21. PMCID: PMC4242985. PMID: 25429173
14. Lebowitz MB, Olson KL, Burns M, Harper MB, Bourgeois F. Drug-drug interactions among hospitalized children receiving chronic antiepileptic drug therapy. Hosp Pediatr. 2016; 6(5): 282-9. DOI: 10.1542/hpeds.2015-0249 [DOI:10.1542/hpeds.2015-0249] [PMID]
15. Ismail M, Iqbal Z, Khattak MB, Khan MI, Arsalan H, Javaid A, et al. Potential drug-drug interactions in internal medicine wards in hospital setting in Pakistan. Int J Clin Pharm. 2013; 35(3): 455-62. DOI: 10.1007/s11096-013-9764-1 [DOI:10.1007/s11096-013-9764-1] [PMID]
16. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003; 58(1): 773-8. DOI: 10.1007/s00228-002-0557-z [DOI:10.1007/s00228-002-0557-z] [PMID]
17. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007; 99(8): 592-600. DOI: 10.1093/jnci/djk130 [DOI:10.1093/jnci/djk130] [PMID]
18. Terman SW, Aubert CE, Hill CE, Maust DT, Betjemann JP, Boyd CM, et al. Polypharmacy in patients with epilepsy: a nationally representative cross-sectional study. Epilepsy Behav. 2020; 111: 107261. DOI: 10.1016/j.yebeh.2020.107261 [DOI:10.1016/j.yebeh.2020.107261] [PMID] []
19. Eyal S, Rasaby S, Ekstein D. Concomitant therapy in people with epilepsy: potential drug-drug interactions and patient awareness. Epilepsy Behav. 2014; 31: 369-76. DOI: 10.1016/j.yebeh.2013.09.041 [DOI:10.1016/j.yebeh.2013.09.041] [PMID]
20. Dickson M, Bramley TJ, Kozma C, Doshi D, Rupnow MF. Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. Am J Health Syst Pharm. 2008; 65(18): 1720-6. DOI: 10.2146/ajhp070508 [DOI:10.2146/ajhp070508] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Attribution-NoneCommercial CC BY-NC